Pro-apoptotic peptide that selectively destroys vasculature supplying white adipose tissue. Studied in primate models with dramatic fat reduction results.
Adipotide is a research compound that was studied as a targeted approach to reducing fat tissue by cutting off its blood supply. It showed striking results in animal studies including primates, but human trials have not been completed. It works very differently from GLP-1 compounds and carries a distinct risk profile.
Fat Tissue Targeting
Adipotide was designed to seek out the blood vessels that supply fat tissue and trigger those cells to self-destruct, cutting off the fat's blood supply. In primate studies, this approach produced significant reductions in body weight and fat mass within weeks.
Obesity Research
Preclinical studies in obese rhesus monkeys showed substantial fat loss and metabolic improvements. These results were published in peer-reviewed literature and generated significant interest in the compound as a potential obesity treatment.
Prostate Cancer Research
The original development of this compound's targeting system was in cancer research, specifically as a way to starve tumors of their blood supply. The fat-targeting application was discovered when researchers found fat tissue blood vessels share similar surface proteins.
Significant fat mass reduction observed in obese primate studies.
Metabolic improvements including insulin sensitivity changes noted alongside fat loss in animal models.
No completed human clinical trials with published efficacy or safety data.
The targeting mechanism appears functional in primates but human translation is unestablished.
Adipotide has not completed human clinical trials. The mechanism — deliberately killing blood vessel cells that supply fat tissue — is aggressive and was associated with kidney toxicity in primate studies, which is a significant safety concern. It is not approved for any use. The animal data, while striking, does not establish safety or effectiveness in humans, and the kidney findings are a serious consideration.
Fat tissue needs a blood supply to survive, just like any other tissue. Adipotide is a peptide designed to home in on a specific protein found on the surface of blood vessel cells that feed fat tissue. When it reaches those cells, it triggers a process of programmed cell death. Without a blood supply, the fat cells that depended on those vessels also die off. The result in animal studies was a relatively rapid reduction in fat mass. The challenge is that this type of targeted vascular destruction can also affect other tissues — in the kidney studies in monkeys, there were signs that the kidneys were being affected, which raised safety flags before human trials advanced.
Kidney toxicity was observed in primate studies of Adipotide, which represents a serious safety concern that has limited advancement to human trials. It is not FDA-approved and has not completed human safety testing. This compound should be considered investigational with an unresolved safety profile.
Preliminary
Most evidence comes from preclinical studies and case reports. Human data is limited and more research is needed.
Published Research Ranges
Primate studies: 0.56mg/kg daily for 28 days; human data extremely limited
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Targeted Apoptosis of Adipose Vasculature by a Prohibitin-Binding Peptide
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.